Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

1 Comparative Effect of Metformin versus Sulfonylureas with Dementia and Parkinson's

2 Disease Risk in US patients over 50 with Type 2 Diabetes Mellitus

- 3 Danielle Newby ^{a,b*}, Andrew B Linden ^c, Marco Fernandes ^a, Yasmina Molero ^{d, e}, Laura
- 4 Winchester^a, William Sproviero^a, Upamanyu Ghose^a, Qingqin S Li^f, Lenore J Launer^g,
- 5 Cornelia van Duijn ^{c,h} & Alejo J Nevado-Holgado ^a
- ⁶ ^a University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK
- 7 ^b Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and
- 8 Musculoskeletal Sciences, University of Oxford, Oxford, UK
- 9 ^c Nuffield Department of Population Health, University of Oxford, Big Data Institute, Li Ka Shing
- 10 Centre for Health Information and Discovery, Oxford, UK
- ¹¹ ^d Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institute, Stockholm, Sweden
- 12 ^e Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- ¹³ ^f Janssen Research & Development, LLC, Titusville, NJ 08560, USA
- 14 ^g National Institute of Aging, Boston, USA
- ¹⁵ ^h Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands 16
- 17 Corresponding author: Dr Danielle Newby <u>danielle.newby@ndorms.ox.ac.uk</u>
- 18 **Current address:** Centre for Statistics in Medicine, Nuffield Department of Orthopaedics,
- 19 Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK Tel.: +44 (0)
- 20 1865 227 374
- 21 **Word count:** 3930 (excluding title page, abstract, references, figures, and tables)
- 22 Keywords: diabetes, metformin, dementia, Parkinson's disease, drug repurposing
- 23 Abbreviations: AD: Alzheimer's disease, PD: Parkinson's disease, VD: vascular dementia,
- 24 MCI: mild cognitive impairment, CKD: Chronic Kidney Disease, eGFR: estimated glomerular
- 25 filtration rate, HbA1c: hemoglobin A1c, NSAIDs: Non-steroidal anti-inflammatory drugs,
- 26 COPD: Chronic obstructive pulmonary disease
- 27 **Short title:** Metformin versus sulfonylureas on Dementia and Parkinson's risk
- 28
- 29

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

30 ABSTRACT

Introduction: Type 2 diabetes is a risk factor for dementia and Parkinson's disease (PD).
Drug treatments for diabetes, such as metformin, could be used as novel treatments for
these neurological conditions. Using electronic health records from the USA (OPTUM®
EHR) we aimed to assess the association of metformin with all cause dementia, dementia
subtypes and PD compared to sulfonylureas.

Research Design and Methods: A new user comparator study design was conducted in patients ≥50 years old with diabetes who were new users of metformin or sulfonylureas between 2006-2018. Primary outcomes were all cause dementia and PD. Secondary outcomes were Alzheimer's disease (AD), vascular dementia (VD) and mild cognitive impairment (MCI). Cox proportional hazard models with inverse probability of treatment weighting (IPTW) were used to estimate the hazard ratios (HR). Sub analyses included stratification by age, race, renal function, and glycemic control.

43 Results: We identified 96,140 and 16,451 new users of metformin and sulfonylureas, 44 respectively. Mean age was 66.4 ± 8.2 years (48% male, 83% Caucasian). Over the 5-year 45 follow-up, 3,207 patients developed all cause dementia (2,256 [2.3%] metformin, 951 [5.8%] 46 sulfonylurea users) and 760 patients developed PD (625 [0.7%] metformin, 135 [0.8%] 47 sulfonylurea users). After IPTW, HRs for all cause dementia and PD were 0.80 (95%CI 48 0.73-0.88) and 1.00 (95%CI 0.79-1.27). HRs for AD, VD and MCI were 0.81 (0.70-0.94), 49 0.79 (0.63–0.99) and 0.91 (0.79–1.04). Stronger associations were observed in patients who 50 were younger (<75 years old), Caucasian, and with moderate renal function.

51 **Conclusions:** Metformin users compared with sulfonylureas users were associated with a 52 lower risk of all cause dementia, AD and VD but not with PD or MCI. Age and renal function 53 modified risk reduction. Our findings support the hypothesis that metformin provides more 54 neuroprotection for dementia than sulfonylureas but not for PD, but further work is required 55 to assess causality.

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

56 What is already known on this topic

- People with type 2 diabetes have increased risk of dementia and Parkinson's disease
- 58 and anti-diabetic drugs such as metformin have been proposed as potential novel

59 treatments for these neurological conditions

- Observational studies have shown inconsistent results regarding the effect of
 metformin on the risk of dementia and PD
- 62 What this study adds
- To our knowledge, this study is the largest of its kind and uses a variety of statistical methods to reduce bias and validate the robustness of the results to examine the association of metformin versus sulfonylureas for multiple neurogenerative outcomes.
- This study supports and extends the current literature regarding the potential
 neuroprotective benefits of metformin.
- Further research is required to understand the underlying neuroprotective
 mechanisms of metformin which may lead to novel drug development opportunities.

71 How this study might affect research, practice or policy

- This study highlights the need for randomized clinical trials and genetic studies to
 confirm our findings to assess causality and understand mechanistic insights which
 could lead to novel disease modifying treatments for dementia
- This study highlights the need for careful consideration of age, race, and renal
 function in selection of participants for clinical trials to address benefits and safety
 concerns for the repurposing of metformin.

78

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

80 INTRODUCTION

Neurodegenerative diseases, such as dementia and Parkinson's disease (PD), are progressive degenerative diseases affecting neurons, which result in irreversible decline in brain functioning. It is estimated there are 50 million people living with dementia worldwide and over 6 million people living with PD, with these numbers predicted to increase substantially over the next decades due to ageing populations[1–3].

86 Type 2 diabetes (diabetes from now on) is a well-established risk factor for dementia[4] and 87 PD[5] indicating a potential shared pathophysiology involving insulin resistance and 88 impaired glucose metabolism[6-8]. Given the potential shared pathophysiology it is not 89 surprising that drugs used to treat diabetes such as metformin are of increased interest for 90 repurposing as possible novel treatments to treat and slow the progression of PD[9,10], 91 cognitive decline and dementia[11]. Metformin is a first line anti diabetic medication that 92 decreases insulin resistance and increases insulin sensitivity[12]. Other anti-diabetic drugs 93 such as sulfonylureas, which are second line anti diabetic drugs, stimulate the release of 94 insulin from pancreatic beta cells[13]. Despite approvals of newer drugs, sulfonylureas 95 remain commonly prescribed after metformin[14]. Previous studies and reviews on the 96 potential neuroprotective properties of metformin have inconsistently reported that metformin 97 is associated with reduced risk of dementia or PD[15-17], increased risk[18,19], and no 98 association[20-22]. Differences in study design, data quality, gender, race representation, 99 confounding may explain some of these inconsistencies.

Given these inconsistencies, the aim of the present study is to examine the associations of the first line anti diabetic drug metformin compared to the second line drug class sulfonylureas with: (i) incident all cause dementia and PD, and (ii) with secondary outcomes of Alzheimer's disease (AD), vascular dementia (VD) and mild cognitive impairment (MCI). In this study, we use a large cohort of patient records from individual-level electronic health

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

records from a large health care provider in the USA (OPTUM® EHR) together with robust methods that address bias and confounding. We carried out sub analysis stratifying our population by age, race, renal function, and glycemic control to understand the impact on these populations. Our approach focussing on both dementia and PD and an analysis approach to reduce bias offers a novel aspect and substantial contribution to existing evidence on the impact of metformin and risk of neurodegenerative diseases.

111 RESEARCH DESIGN AND METHODS

112 Study Design and Setting

113 A new user active comparator study was carried out to determine the comparative effect of 114 metformin versus sulfonylureas users on dementia risk over a 5-year follow up based on an 115 intention-to-treat approach. We used OPTUM® deidentified Electronic Health Records 116 (OPTUM® EHR) dataset containing data from primary care and secondary care facilities 117 from over 100 million patients across the US general population [23]. We had access to 118 patient data from 01/01/2006 to 01/12/2018 for patients aged 40 years or older. Patient data 119 was mapped to the Observational Medical Outcomes Partnership Common Data Model 120 (CDM) v5.3.1[24].

121 Participants

122 We included patients who were 50 years or older with a diagnosis of diabetes and at least 1 123 year of observational data between 2006 and 2018. Included patients were required to have 124 at least 1 year of follow-up in the database prior to first prescription of metformin or 125 sulfonylureas (baseline) and be free of any diagnosis of dementia, MCI, or PD prior to their 126 first prescription. Patients with polycystic ovary syndrome were excluded due to off label use 127 of metformin. Since renal function can drive choice of anti-diabetic prescription, included 128 patients were required to have an estimated glomerular filtration rate (eGFR) measure (or 129 related clinical diagnosis) and a hemoglobin A1c (HbA1c) measurement 1 year before 130 metformin or sulfonylurea initiation. Those with chronic kidney disease (CKD) levels 4 and 5

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

131 as well as HbA1c levels > 9% were excluded as this is not indicative of metformin new 132 users. Only patients who remained on monotherapy of either metformin or sulfonylureas for 133 2 years following first prescription were included in this study. Follow-up began after this 2-134 year period and lasted until the end of the 5 years, death, or dementia/PD diagnosis, 135 whichever occurred first. During follow-up, participants could take additional diabetes 136 medications, but those who switched between metformin and sulfonylureas were excluded.

137 Variables and data sources

Comorbidities were defined by standard concepts codes based on SNOMED nomenclature using ATHENA (<u>https://athena.ohdsi.org/search-terms/terms</u>) and PHEOBE (<u>https://data.ohdsi.org/PHOEBE/</u>) tools. Clinical codes used define outcome, exposure and all other variables can be found in the **Supporting Information (Table S1 and 2)**.

142 Primary outcomes were all cause dementia or PD defined using a combination of diagnosis 143 and prescription records. Secondary outcomes included diagnosis of AD, VD and MCI. 144 Metformin or sulfonylurea use was extracted from patient prescriptions defined by standard 145 concepts codes based on RxNorm nomenclatures. Sulfonylureas consisted of 146 acetohexamide, carbutamide, chlorpropamide, tolazamide, tolbutamide, glibenclamide 147 (glyburide), glibornuride, gliclazide, glipizide, gliguidone, glisoxepide, glyclopyramide or 148 glimepiride. At least two prescriptions per year between baseline and the beginning of follow-149 up were required.

The 33 covariates used in this study were age (dichotomized at 75 years), gender, BMI, race (Caucasian, African American, Asian, other/unknown), smoking status (Current, previous, never, missing), US state region, comorbidities [angina, arthritis, atrial fibrillation, cancer, chronic obstructive pulmonary disease (COPD), CKD diagnosis and stages, coronary heart disease, eye disease, hypertension, heart attack, heart failure, high cholesterol, head injury, psychiatric disorders, peripheral arterial disease, substance abuse, stroke], health care utilisation (number of outpatient visits), year of first prescription, lab measurements (HbA1c,

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

157 eGFR) and medications (ACE inhibitors, glucocorticoids, nonsteroidal anti-inflammatory 158 drugs (NSAIDS), beta-2 agonists, diuretics and angiotensin receptor blockers. For 159 measurement variables (i.e., HbA1c, eGFR, BMI etc), the value closest to baseline date 160 within 1 year before metformin or sulfonylurea prescription was taken unless otherwise 161 stated. BMI was calculated from height and weight when not reported directly. Height 162 measurements within 5 years before baseline were allowed. BMI measurements lower than 163 15 kg/m² and greater than 60 kg/m² were removed, which is consistent with previous 164 studies[25]. For smoking, unknown or contradictory measurements on the same day were 165 removed. HbA1c values $\leq 2\%$ were removed. CKD stage was extracted from diagnostics 166 codes or from eGFR values. Other medications (ACE inhibitors, NSAIDS etc) were defined 167 as at least two prescriptions one year prior to drug initiation.

168 Statistical methods

169 Baseline demographics were assessed using standardized mean differences (SMD). We 170 carried out a new user comparator study [26] to estimate the effect of metformin versus 171 sulfonylureas. A new user design excludes prevalent cases to reduce immortal time and 172 survivor biases. To account for confounding by indication, we utilised propensity scores (PS) 173 and implemented inverse probability of treatment weighting (IPTW)[27] to balance the 174 baseline characteristics. To create the PS model, we included 33 variables specified 175 previously. For BMI, smoking status, race and location, the missing indicator method was 176 utilised to account for missingness[28]. IPTW were created and trimmed at 20. We assessed 177 balance between our groups using SMD with a difference of less than 0.1 (i.e., 10%) 178 indicating an acceptable balance between covariates, with metformin and sulfonylurea users 179 after IPTW[29]. Cox proportional hazards models were used with IPTW to estimate the risk 180 of subsequent primary (all cause dementia, PD) and secondary outcomes (AD, VD, MCI). 181 The proportional hazards assumption was evaluated using Kaplan-Meier survival curves. 182 Where proportional hazards assumption were violated analyses were repeated using piece 183 wise Cox regression. Five negative control outcomes (impacted cerumen, tinnitus, cramp of

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

184 limb, snoring and impingement syndrome of shoulder region)[30] were used to identify185 residual confounding unaccounted for by IPTW.

186 We firstly carried out the analysis using the whole cohort secondly split by age (cut off 75 187 years) for primary outcomes (all cause dementia, PD) and secondary outcomes (AD, VD, 188 MCI) with and without adjustment for IPTW. In sub analyses, we compared the risk of 189 outcome in patients with differing renal function, HbA1c levels and race. We dichotomized 190 eGFR based on CKD staging into three groups (normal [eGFR > 90 mL/min]), moderate 191 (eGFR = 60-89 mL/min) and poor renal function (eGFR =< 60 mL/min)) and HbA1c at 192 baseline, was dichotomized at 7%, reflecting diabetes treatment guidelines. We additionally 193 carried out a variety of sensitivity analyses to test the robustness of our results. Since 194 diagnosis codes for MCI might capture impairment but this impairment may not be severe 195 enough to qualify as dementia, we carried out a sensitivity analysis by combining diagnostic 196 codes from MCI and dementia. Although patients had been on monotherapy use for 2 years 197 before follow-up there remained the potential for the impact of dementia or PD to influence 198 medication use. Further sensitivity analysis involved excluding those with a dementia or PD 199 diagnosis less than 1 year after follow-up to account for potential protopathic bias (i.e., 200 reverse causation). Finally, for the main analysis we followed an intent-to-treat framework 201 therefore we carried out an on-treatment analysis in which discontinued metformin or 202 sulfonylureas use was censored.

203 **RESULTS**

204 **Participants**

Between 2006 and 2018, we identified 96,140 new users of metformin and 16,451 new users of sulfonylureas (n = 112,591). A flow diagram showing how these numbers were obtained after inclusion and exclusion criteria is shown in **Figure 1**.

208

209

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

210

211

<<FIGURE 1>>

212 Characteristics of baseline population

213 From the study population, the mean age (\pm SD) was 66.4 \pm 8.2 years (metformin users 214 mean age 65.7 ± 7.83) and sulfonylureas mean age 71.0 ± 8.71), 48% male, 83% 215 Caucasian with a mean HbA1c of $6.79\% \pm 0.76$. In the sample population, 3,207 patients 216 developed any dementia (2,256 among metformin and 951 sulfonylurea users) and 760 217 patients developed PD (625 among metformin and 135 sulfonylurea users). All cause 218 dementia rates were 7.77 and 17.73 per 1000 person-years in metformin and sulfonylureas 219 users, respectively. PD rates were 2.13 and 2.45 per 1000 person-years in metformin and 220 sulfonylureas users, respectively. Metformin users were younger, have better renal function, 221 fewer comorbidities, and take different associated medications (NSAID's, diuretics and 222 glucocorticoids) compared to sulfonylurea users (Table 1). For BMI, 26% of observations 223 were missing (24% for metformin users and 33% for sulfonylureas users) and for eGFR 224 0.1% of observations were missing (0.08% for metformin users and 0.38% for sulfonylureas 225 users).

Table 1. Baseline characteristics of 112,591 patients over 50 years old with type 2 diabetes who were new users of either metformin or sulfonylureas between 2006-2018 before balancing of characteristics using inverse probability of treatment weighting

229 (IPTW)

Description	Metformin	Sulfonylureas	SMD (%)
n	96140	16451	
Gender (% male)	46107 (48.0)	8439 (51.3)	6.7
Race (%)			4.3
African American	9659 (10.0)	1535 (9.3)	
Asian	2394 (2.5)	328 (2.0)	
Caucasian	79693 (82.9)	13853 (84.2)	
Other/Unknown	4394 (4.6)	735 (4.5)	
Age at Baseline (mean [SD])	65.65 (7.83)	70.98 (8.71)	64.4
Age Category: < 75 years	81258 (84.5)	9690 (58.9)	59.3
US Region			10.5

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

Midwest (%)	51871 (54.0)	9232 (56.1)	
Northeast (%)	11430 (11.9)	2294 (13.9)	
South (%)	24678 (25.7)	3706 (22.5)	
West (%)	6153 (6.4)	850 (5.2)	
Unknown (%)	2008 (2.1)	369 (2.2)	
eGFR (mean [SD])	88.47 (16.43)	75.48 (21.73)	67.4
CKD Group (%)			67.2
Stage 1	46980 (48.9)	4464 (27.1)	
Stage 2	44276 (46.1)	7708 (46.9)	
Stage 3	4884 (5.1)	4279 (26.0)	
Smoking Status (%)			18.1
Missing	39916 (41.5)	8078 (49.1)	
Current	7992 (8.3)	1083 (6.6)	
Never	24377 (25.4)	3197 (19.4)	
Previous	23855 (24.8)	4093 (24.9)	
HbA1c (mean [SD])	6.76 (0.75)	6.95 (0.83)	24.3
BMI (mean [SD])	33.46 (6.63)	32.24 (6.60)	18.6
BMI Group			25.8
Missing	23243 (24.2)	5481 (33.3)	
Underweight (<20kg/mg ²)	276 (0.3)	86 (0.5)	
Normal (20-25kg/mg ²)	4701 (4.9)	1084 (6.6)	
Overweight (25-30kg/mg ²)	18766 (19.5)	3302 (20.1)	
Obese (>30kg/mg ²)	49154 (51.1)	6498 (39.5)	
HbA1c Group			27.3
HbA1c: < 7% (< 53 mmol/mol)	62460 (65.0)	8583 (52.2)	
HbA1c: 7-8% (53 -64 mmol/mol)	26245 (27.3)	5721 (34.8)	
HbA1c: > 8 (> 64 mmol/mol)	7435 (7.7)	2147 (13.1)	
Length of Follow-up in Years (mean (SD))	3.02 (1.59)	3.26 (1.60)	15
Year at Frist Prescription (%)			34.7
2007-2008	9016 (9.4)	3190 (19.4)	
2009-2010	13001 (13.5)	2696 (16.4)	
2011-2012	21752 (22.6)	3748 (22.8)	
2013-2014	30202 (31.4)	4325 (26.3)	
2015-2016	22169 (23.1)	2492 (15.1)	
Number of Outpatient Visits prior to baseline (mean [SD])	24.36 (30.39)	25.74 (34.85)	4.2
All cause dementia (%)	2256 (2.3)	951 (5.8)	17.5
AD (%)	754 (0.8)	337 (2.1)	11.1
VD (%)	349 (0.4)	154 (1.0)	7.5
MCI (%)	1414 (1.5)	401 (2.6)	7.5
PD (%)	625 (0.7)	135 (0.8)	2
Hypertension (%)	68050 (70.8)	11601 (70.5)	0.6
COPD (%)	5483 (5.7)	1194 (7.3)	6.3
Chronic Kidney Disease (%)	4655 (4.8)	2740 (16.7)	38.9

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

Stroke/TIA (%)	2147 (2.2)	562 (3.4)	7.1
Heart Attack (%)	954 (1.0)	224 (1.4)	3.4
Angina (%)	11081 (11.5)	1898 (11.5)	0
Heart Failure (%)	2494 (2.6)	1126 (6.8)	20.1
Atrial Fibrillation (%)	9636 (10.0)	2256 (13.7)	11.4
Coronary Artery Disease (%)	1844 (1.9)	535 (3.3)	8.4
Substance Abuse (%)	1131 (1.2)	176 (1.1)	1
Hyperlipidemia (%)	69957 (72.8)	11026 (67.0)	12.5
Head Injury (%)	537 (0.6)	114 (0.7)	1.7
Arthritis (%)	18726 (19.5)	3057 (18.6)	2.3
Major Psychiatric Disorders (%)	11372 (11.8)	1423 (8.6)	10.5
Peripheral Arterial Disease (%)	3287 (3.4)	998 (6.1)	12.5
Eye Disease (%)	3598 (3.7)	711 (4.3)	2.9
Cancer (%)	4275 (4.4)	981 (6.0)	6.8
Ace Inhibitors (%)	38748 (40.3)	7426 (45.1)	9.8
Diuretics (%)	25846 (26.9)	3930 (23.9)	6.9
Beta 2 Agonists (%)	35593 (37.0)	5530 (33.6)	7.1
Angiotensin II Receptor Blockers (%)	21623 (22.5)	3482 (21.2)	3.2
Glucocorticoids (%)	49438 (51.4)	8533 (51.9)	0.9
NSAIDs (%)	32424 (33.7)	4332 (26.3)	16.2

Abbreviations: AD: Alzheimer's Disease, VD: vascular Dementia, CKD: Chronic Kidney Disease; eGFR: Estimated glomerular filtration rate by measured laboratory value using Mayo Clinic Quadratic. HbA1c: haemoglobin A1c; COPD: Chronic obstructive pulmonary disease; MCI: mild cognitive impairment; TIA: Transient ischaemic attack, NSAIDs: Non-steroidal anti-inflammatory drugs, SMD (%): standardized mean difference – values >10% indicate significant imbalance between groups. CKD group defined using eGFR and/or diagnosis code.

After IPTW, all variables were balanced between the two groups for the main analysis (SMD <0.1) (**Figure 2**). For sub analyses (age, race, renal function, and HbA1c) all variables were balanced apart from the race sub analysis where the variable "HbA1c <7%" was unbalanced for the race group "unknown/other" (**Supporting information Figures S1-11**).

240

241

242

<< FIGURE 2>>

Association of new users of metformin versus sulfonylureas with all cause dementia and PD risk

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

245 For primary outcomes, using Cox regression with IPTW, there was a lower risk of all cause 246 dementia (HR 0.80; 95%CI 0.73-0.88) when comparing metformin users with sulfonylurea 247 users, but no difference when comparing risk of PD (HR 1.00; 95%CI 0.79-1.27) (Figure 3). 248 For secondary outcomes, there was a lower risk of AD (HR 0.81; 95%CI 0.70-0.94) but not 249 for VD or MCI. However, the direction of the effects on VD and MCI, the effects are 250 consistent with lower risk for metformin users. We found that the associations were stronger 251 in the younger (age <75) for all cause dementia and secondary outcomes and attenuated in 252 older ages (≥75 years) (Figure 3). There were fewer patients who started antidiabetic 253 treatment after age 75 compared to before 75 (19% vs. 81%, respectively) although average 254 follow-up length were similar (3.04 vs. 3.06 years). For PD, the older stratum showed an 255 increased risk of PD for metformin users versus sulfonylurea users. All unadjusted hazard 256 ratios for all models can be found in the supporting information (Tables S4-6).

- 257
- 258

<< FIGURE 3>>

259

260 Using Kaplan-Meier survival curves, the proportional hazards assumption held for all cause 261 dementia, AD, MCI, and PD in Figure 3 apart from VD where there was deviation of 262 proportional hazards at around 2.5 years (Supporting information Figure S12). Therefore, 263 we repeated the analysis for the whole population using a piece wise Cox regression split at 264 2.5 years. The results showed only showed a lower HR for metformin users after 2.5 years 265 (HR 0.64; 95%CI 0.45-0.89) (Supporting information Table S7). For sensitivity analyses, 266 changing to an on-treatment analysis further decreased HRs in favor of metformin for all 267 cause dementia (HR 0.76; 95%CI 0.68-0.84) (Supporting Information Table S8). Removal 268 of patients who were diagnosed within 1 year of follow-up attenuated results for AD but did 269 not change the results for other outcomes (Supporting Information Table S9). Combining 270 the earliest dates from MCI and all cause dementia diagnosis had little impact on results (HR 271 0.82; 95%CI 0.75-0.89). Adjusted hazard ratios for the negative control outcomes were 1.04 272 (0.96–1.13) for impacted cerumen, 1.10 (0.95–1.30) for tinnitus, 1.01 (0.87–1.18) for cramp

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

273 in limb, 1.06 (0.91–1.24) for snoring, and 1.16 (0.96–1.41) for shoulder impingement

274 (Supporting Information Figure S13).

275 The influence of race, renal function, and glycemic control between new users of

276 metformin versus sulfonylureas with dementia and PD risk

277 In subgroup analyses we explored if our outcomes were influenced by renal function,

278 glycemic control, or race (**Figure 4**).

- 279
- 280

<< FIGURE 4>>

281

282 In the race subgroup analysis, after IPTW adjustment, metformin users who were Caucasian 283 (n = 94,395) had a lower risk of all cause dementia (HR 0.79; 95%CI 0.71-0.87), AD (HR 284 0.77; 95%CI 0.65-0.90) or in sensitivity analysis > 2.5 years for VD (HR 0.64; 95%CI 0.44-285 0.94 **Supporting Information Table S7**). There were no differences for other outcomes 286 compared to sulfonylurea users (Figure 4). There were no differences in risk for other races 287 however sample numbers were lower (African American 11,224, Asian 2,735, and 288 other/unknown 5,156). In the renal function subgroup analysis, metformin users with 289 moderate renal function were associated with lower all cause dementia and AD but no 290 differences in risk for PD for any renal function group (Figure 4). For VD, metformin users 291 had a lower HR after 2.5 years (HR 0.59; 95%CI 0.35-0.99) (Supporting Information 292 **Table S7**). In the glycemic control subgroup analysis, stratifying on baseline HbA1c, 293 metformin users with either low or high HbA1c levels were associated with a lower risk of all 294 cause dementia or AD but only HbA1c \geq 7% levels for VD (HR 0.67; 95%CI 0.48-0.94) which 295 in sensitivity analysis showed risk was lower after 2.5 years (HR 0.57; 95%CI 0.35-0.93). 296 Unadjusted HRs for for all subgroup analyses in Figure 4 can be found in the supporting 297 information (Table S6).

298 **DISCUSSION**

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

299 In this new user active comparator study of 112,591 patients with diabetes, we found new 300 metformin users were associated with ~20% lower risk of all dementia, AD and VD 301 compared sulfonylureas users but there was no difference in PD risk or MCI. A lower risk of 302 dementia in metformin users was also seen in subsets of patients who were younger (<75 303 years), Caucasian, and those with moderate renal function but there were no differences in 304 risk in subsets with different glycemic control. Our findings support the hypothesis that 305 metformin may provide more neuroprotection for dementia than sulfonylureas but not for PD 306 or MCI.

307 Our results agree with similar active comparator studies, which show a reduction in risk for 308 all cause dementia in new users of metformin, despite these studies using either smaller, 309 older, or mainly male populations [15,16,31]. A study using patients older than 65 years from 310 the USA Veterans Affairs (VA) database [15] showed a lower risk of all cause dementia in 311 those younger than 75 years old for metformin users (HR 0.89 95%CI 0.79-0.99 n 28,640) 312 but not for AD or VD. However, a lack of precision in recording specific diagnosis of 313 dementia, with difficulties in discriminating between AD and other causes, leading to 314 underreporting of specific dementia diagnosis[32]. This could explain why previous studies 315 and our present study have not shown reduction of risk in dementia disease subtypes when 316 stratifying on age[33]. Our results and three other studies [15,31,34] differ from other studies 317 [19,35,36] which report no association or increased risk of dementia in metformin users 318 because these studies did not consider confounding by indication. Therefore, results 319 obtained from these studies may reflect the differences between the characteristics of the 320 anti-diabetic drug users rather than true treatment effects. Despite these inconsistencies a 321 Mendelian randomization study has shown metformin reduces AD risk with the NDUFA2 322 gene and mitochondrial function proposed as potential mechanisms in dementia 323 protection[37]. For patients with VD our results showed there was only a lower risk after 2.5 324 years of metformin treatment concurrent with a previous study[21] which showed lower risk

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

of dementia and AD after longer term use greater than 2 years in patients from the veteran's
 affairs database (n 5528).

We did not find any association between metformin and MCI compared with sulfonylureas.
MCI populations could contain a mixture of patients who do or do not convert to dementia.
This heterogeneity may have reduced our power to detect any differences. However, a
randomized controlled trial in patients with amnestic MCI indicated metformin users had
better total recall after 12 months but not for other cognitive tests (MMSE, ADAS-cog)[38].
Interestingly, this trial showed that those who were younger, on the highest dose, without
APOE-ε4 and with lower HbA1c had the most benefit.

334 For PD, there are no active comparator studies which compare new users of metformin 335 versus sulfonylureas only direct comparator studies which compare drug use versus no drug 336 use. One study using USA veteran data, showed those who took metformin >2 years had 337 lower risk of PD (HR 0.30 95%CI 0.18-0.85)[21] compared to non users. However, nearly 338 30% of non-metformin users were taking other anti-diabetic medications. These results 339 contradict a study using data from Taiwan which showed metformin users are at increased 340 risk of PD (HR 2.27 95%CI 1.68-307)[19]. Direct effect studies comparing drug use versus 341 no drug use are prone to confounding by indication and immortal time bias making 342 observational studies difficult to interpret and generalize. Despite inconsistent results of 343 observational studies there is evidence from *in vitro*, non-clinical and genetic studies which 344 highlight the potential neuroprotective benefits of metformin[10,39,40]. In a Mendelian 345 randomization study, greater genetically predicted expression level of NDUFAF2 in brain, the 346 putative target of metformin, was shown to decrease the risk of PD[11]. This means that 347 although there was no difference in risk between metformin users and sulfonylureas users 348 observed our study, it remains possible that metformin could reduce risk of PD compared to 349 those not taking metformin or other anti-diabetics.

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

350 Our age specific findings are consistent with previous studies which indicate metformin may 351 have more benefit for reducing dementia risk for those who initiate the treatment at a 352 younger age[15,31]. We also showed that there were, albeit smaller, benefits in those who 353 were older than 75 years. Differences in study inclusion criteria, demographics and size of 354 patient populations could explain this difference. Moreover, older patients have more 355 comorbidities which contribute to dementia risk and hence attenuate any positive drug 356 effects of metformin. We additionally showed that PD risk was higher in metformin users in 357 those older than 75 years old which is consistent with a recent meta-analysis and systematic 358 review (OR 1.66, 95%CI 1.14 to 2.42)[18], however our confidence intervals were large and 359 close to the null (HR 1.40 95%CI 1.01-1.95) so caution must be taken with this result. In this 360 study we found baseline HbA1c levels did not modify the effect of metformin on dementia or 361 PD risk which also consistent withs previous studies[15,34]. This could indicate that 362 metformin's neuroprotective effect is unlikely to be due to better diabetic control but via other 363 mechanisms[34,41].

364 We did not see protective effects of metformin in different race groups apart from Caucasian 365 patients which were the most represented group in our study (83%). These results are 366 consistent with other studies [15,31], but are contradicted by one [16] who showed that 367 African American patients taking metformin were associated with a reduction in dementia 368 risk and no reduction in risk in Caucasian patients. Differences in these results and ours 369 might be explained by our eligibility criteria, which included 2 years of continuous metformin 370 or sulfonylurea use. Our exclusion criteria may have removed patients from 371 underrepresented populations who may have a higher burden of diabetes-related 372 complications and may escalate quicker from monotherapy metformin or sulfonylurea use 373 limiting the generalizability of our results[42].

For renal function, contradictory to a previous study[15] we found that metformin users with normal renal function did not have any difference in dementia or PD risk compared to sulfonylurea users. However, this study[15] only categorized renal function into two

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

categories (split by eGFR 60 mL/min) whereas we split renal function into three groups (normal eGFR > 90 mL/min, moderate eGFR = 60-89 mL/min and poor eGFR \leq 60 mL/min). Our results indicated that metformin users with poor renal function (eGFR \leq 60 mL/min) may have reduced dementia and AD risk. However, this group was much smaller potentially due to the contradictions of metformin in those with renal disease.

382 There are many strengths of this study. Firstly, the large sample size allowed us to 383 investigate the impact not only of all cause dementia but also specific causes of dementia, 384 such as Alzheimer's disease and vascular dementia. We used data from both genders unlike 385 other studies which had >90% male populations[15,21]. We carried out a new user active 386 comparative cohort study design, with IPTW, nested within a population of patients with 387 diabetes to reduce confounding by indication and other biases. We additionally tested five 388 negative control outcomes which provided reassurance that no significant residual 389 confounding remained after adjusting the mentioned covariates using IPTW methods.

Limitations of our study are as follows. Firstly, although we addressed many sources of confounding, it is possible that some sources of confounding were unavailable or inadequately measured such as physical activity, education, and diet[4,43]. Furthermore, we used data from OPTUM® EHR from USA which could reduce the generalisability of our results due to potential differences in prescription patterns, comorbidities, incidence of diabetes and dementia in other countries.

Secondly, dementia and PD tend to be under-diagnosed and under-recorded[32,44], which may lead to measurement errors in our outcomes and would tend to lead associations towards the null. We used both diagnosis and prescription records to define our outcomes which could lead to misclassification due to the off-label use of certain medications[45,46]. Thirdly, we carried out an intention-to-treat analysis and did not include potential add-on drugs treatments that occurred later or consider antidiabetic treatment switches. This may be a possible source of confounding and could result in a lack in generalizability. Fourthly, for

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

403 dementia and PD, there is a long prodromal and/or preclinical periods[47,48] which may 404 impact treatment choice and, although in our sensitivity analysis we removed those with a 405 diagnosis less than 1 year from the start of follow up, this might not be long enough to 406 completely remove reverse causation biases. Finally, it has been shown that metformin 407 reduces mortality in patients with diabetes[49], therefore the competing risk of death could 408 affect our results and interpretation. A recent study[34], jointly modelled risk of dementia and 409 death with metformin versus sulfonylureas and showed that the competing risk of death is 410 highly dependent on the baseline mortality rate of the population.

411 CONCLUSIONS

412 To our knowledge, this study is the largest of its kind and uses a variety of statistical 413 methods to reduce bias and validate the robustness of the results. This study supports and 414 extends the current literature regarding the potential neuroprotective benefits of metformin. 415 The clinical applicability of this study showing potential neuroprotection of metformin is 416 highlighted by recent clinical trials underway investigating metformin for the prevention of 417 cognitive impairment and dementia[11,50]. Furthermore, recent genetic studies also 418 highlight causal effects between metformin and dementia. This work highlights the need for 419 careful consideration of age, race, and renal function in selection of participants for clinical 420 trials to address benefits and safety concerns for the repurposing of metformin. Further 421 research is required to understand the underlying neuroprotective mechanisms of metformin 422 which may lead to novel drug development opportunities.

423 **DECLARATIONS**

424 Data availability statement

425 Data may be obtained from a third party (OPTUM® EHR) and are not publicly available. The 426 analysis code available via the corresponding author upon request.

427 **Competing interests**

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

- 428 Alejo J. Nevado-Holgado has received funding from Janssen Pharmaceuticals,
- 429 GlaxoSmithKline and Ono Pharma. QSL is an employee of Janssen Research &
- 430 Development, LLC, of Johnson & Johnson, and may hold equity in Johnson & Johnson. All
- 431 other authors declare no conflicts of interest

432 Funding

- 433 This work was supported by Janssen Pharmaceuticals. Lenore J. Launer is supported by the
- 434 National Institute on Aging Intramural Research Programme, US. Additional funds were
- 435 provided by Rosetrees Trust (M937) and John Black Charitable Fund (ID A2926). The
- 436 funding sources has no role in the study design; in the collection, analysis, and interpretation
- 437 of data; in the writing of the report; and in the decision to submit the paper for publication.

438 Author contributions

- 439 DN designed the study with input from LL, QSL and YM. MF carried out data curation and
- 440 DN carried out all analyses. DN wrote the manuscript with input from all authors. All authors
- 441 reviewed the final manuscript and consent for publication.

442 Acknowledgments

443 We thank John Isaac (Janssen Pharmaceuticals) for initial discussions.

444 **REFERENCES**

- Martin Prince A, Wimo A, Guerchet M, *et al.* World Alzheimer Report 2015 The
 Global Impact of Dementia An Analysis of Prevalence, Incidence, Cost and Trends.
 2015.
- Ou Z, Pan J, Tang S, *et al.* Global Trends in the Incidence, Prevalence, and Years
 Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990
 to 2019. *Frontiers in Public Health* 2021;**9**:1994.
- 451 doi:10.3389/FPUBH.2021.776847/BIBTEX
- Ray Dorsey E, Elbaz A, Nichols E, *et al.* Global, regional, and national burden of
 Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of
 Disease Study 2016. *The Lancet Neurology* 2018;**17**:939–53. doi:10.1016/S1474-
- 455 4422(18)30295-3/ATTACHMENT/30B76483-5DB3-41F7-993B-
- 456 E817505F2129/MMC1.PDF
- 4574Livingston G, Huntley J, Sommerlad A, *et al.* Dementia prevention, intervention, and458care: 2020 report of the Lancet Commission. *Lancet* 2020;**396**:413–46.
- 459 doi:10.1016/S0140-6736(20)30367-6

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

	_	
460	5	Hassan A, Kandel RS, Mishra R, et al. Diabetes Mellitus and Parkinson's Disease:
461		Shared Pathophysiological Links and Possible Therapeutic Implications. Cureus
462		2020; 12 . doi:10.7759/CUREUS.9853
463	6	Karki R, Kodamullil AT, Hofmann-Apitius M. Comorbidity Analysis between
464		Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared
465		Pathways and the Role of T2DM Drugs. J Alzheimers Dis 2017;60:721–31.
466		doi:10.3233/JAD-170440
467	7	Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: A new target for
468	,	disease modification? <i>Progress in Neurobiology</i> 2016; 145–146 :98–120.
469		doi:10.1016/J.PNEUROBIO.2016.10.001
470	8	Firbank MJ, Yarnall AJ, Lawson RA, <i>et al.</i> Cerebral glucose metabolism and cognition
	0	
471		in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Journal of Neurology</i> ,
472	0	Neurosurgery & Psychiatry 2017;88:310–6. doi:10.1136/JNNP-2016-313918
473	9	Agostini F, Masato A, Bubacco L, et al. Metformin Repurposing for Parkinson
474		Disease Therapy: Opportunities and Challenges. International Journal of Molecular
475		Sciences 2022;23. doi:10.3390/IJMS23010398
476	10	Storm CS, Kia DA, Almramhi MM, et al. Finding genetically-supported drug targets
477		for Parkinson's disease using Mendelian randomization of the druggable genome.
478		Nature Communications 2021 12:1 2021;12:1-14. doi:10.1038/s41467-021-26280-1
479	11	MET formin and FINGER Intervention to Prevent Cognitive Impairment and Disability
480		in Older Adults at Risk for Dementia - Full Text View - Clinical Trials.gov.
481		https://clinicaltrials.gov/ct2/show/NCT05109169 (accessed 23 Mar 2022).
482	12	Rojas LBA, Gomes MB. Metformin: An old but still the best treatment for type 2
483		diabetes. Diabetology and Metabolic Syndrome. 2013;5. doi:10.1186/1758-5996-5-6
484	13	Sola D, Rossi L, Schianca GPC, <i>et al.</i> Sulfonylureas and their use in clinical practice.
485	15	Archives of Medical Science : AMS 2015;11:840. doi:10.5114/AOMS.2015.53304
486	14	Roglic G, Norris SL. Medicines for Treatment Intensification in Type 2 Diabetes and
480	14	Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of
488		the World Health Organization Guidelines on Second- and Third-Line Medicines and
489		Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With
490		Diabetes Mellitus. Ann Intern Med 2018;169:394–7. doi:10.7326/M18-1149
491	15	Orkaby AR, Cho K, Cormack J, et al. Metformin vs sulfonylurea use and risk of
492		dementia in US veterans aged \$65 years with diabetes. <i>Neurology</i> 2017;89:1877-85.
493		doi:10.1212/WNL.000000000004586
494	16	Scherrer JF, Morley JE, Salas J, et al. Association between metformin initiation and
495		incident dementia among African American and white veterans health administration
496		patients. Annals of Family Medicine 2019;17:352-62. doi:10.1370/afm.2415
497	17	Campbell JM, Stephenson MD, De Courten B, et al. Metformin Use Associated with
498		Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-
499		Analysis. Journal of Alzheimer's Disease 2018;65:1225–36. doi:10.3233/JAD-180263
500	18	Ping F, Jiang N, Li Y. Association between metformin and neurodegenerative diseases
501		of observational studies: systematic review and meta-analysis. BMJ Open Diabetes
502		<i>Research and Care</i> 2020; 8 :e001370. doi:10.1136/BMJDRC-2020-001370
502	19	Kuan YC, Huang KW, Lin CL, <i>et al.</i> Effects of metformin exposure on
503 504	17	neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. <i>Prog</i>
504		Neuropsychopharmacol Biol Psychiatry 2017; 79 :77–83.
505 506		doi:10.1016/J.PNPBP.2017.06.002
	20	
507	20	Sluggett JK, Koponen M, Simon Bell J, <i>et al.</i> Metformin and Risk of Alzheimer's
508		Disease Among Community-Dwelling People With Diabetes: A National Case-Control
509		Study. J Clin Endocrinol Metab 2020;105:E963–72. doi:10.1210/CLINEM/DGZ234

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

510 511 512	21	Shi Q, Liu S, Fonseca VA, <i>et al.</i> Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. <i>BMJ Open</i> 2019; 9 . doi:10.1136/bmjopen-2018-024954
513 514 515	22	Qin X, Zhang X, Li P, <i>et al.</i> Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> 2021; 12 :1155. doi:10.3389/FNEUR.2021.678649/BIBTEX
516 517	23	Wallace PJ, Shah ND, Dennen T, <i>et al.</i> Optum Labs: Building A Novel Node In The Learning Health Care System. <i>Health Affairs</i> 2014; 33 :1187–94.
518 519 520	24	doi:10.1377/hlthaff.2014.0038 Marc Overhage J, Ryan PB, Reich CG, <i>et al.</i> Validation of a common data model for active safety surveillance research. <i>J Am Med Inform Assoc</i> 2012; 19 :54–60.
521 522 523	25	doi:10.1136/AMIAJNL-2011-000376 Newby D, Prieto-Alhambra D, Duarte-Salles T, <i>et al.</i> Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database
524 525 526	26	case-control study. <i>Alzheimers Res Ther</i> 2020; 12 . doi:10.1186/S13195-020-00606-5 The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision
527 528 529	27	8). EMA/95098/2010 http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf. Curtis LH, Hammill BG, Eisenstein EL, <i>et al.</i> Using inverse probability-weighted
530 531		estimators in comparative effectiveness analyses with observational databases. <i>Med Care</i> 2007; 45 . doi:10.1097/MLR.0B013E31806518AC
532 533 534	28	Groenwold RHH, White IR, Donders ART, <i>et al.</i> Missing covariate data in clinical research: When and when not to use the missing-indicator method for analysis. <i>CMAJ</i> 2012; 184 :1265–9. doi:10.1503/CMAJ.110977/-/DC1
535 536 537	29	Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. <i>Stat Med</i> 2009; 28 :3083–107. doi:10.1002/SIM.3697
538 539	30	Arnold BF, Ercumen A, Benjamin-Chung J, <i>et al.</i> Brief report: Negative controls to detect selection bias and measurement bias in epidemiologic studies. <i>Epidemiology</i>
540 541 542	31	2016; 27 :637–41. doi:10.1097/EDE.000000000000000504 Scherrer JF, Salas J, Floyd JS, <i>et al.</i> Metformin and Sulfonylurea Use and Risk of Incident Dementia. <i>Mayo Clin Proc</i> 2019; 94 :1444.
543 544 545	32	doi:10.1016/J.MAYOCP.2019.01.004 Davis KAS, Mueller C, Ashworth M, <i>et al.</i> What gets recorded, counts: dementia recording in primary care compared with a specialist database. <i>Age Ageing</i>
546 547 548 549	33	2021; 50 :2206–13. doi:10.1093/AGEING/AFAB164 McKhann GM, Knopman DS, Chertkow H, <i>et al.</i> The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
550 551 552	34	<i>Alzheimers Dement</i> 2011; 7 :263–9. doi:10.1016/J.JALZ.2011.03.005 Charpignon M-L, Vakulenko-Lagun B, Zheng B, <i>et al.</i> Drug repurposing of metformin for Alzheimer's disease: Combining causal inference in medical records data and
553 554 555	35	systems pharmacology for biomarker identification. <i>medRxiv</i> 2021;:2021.08.10.21261747. doi:10.1101/2021.08.10.21261747 Weinstein G, Davis-Plourde KL, Conner S, <i>et al.</i> Association of metformin,
555 556 557 558	55	sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts. <i>PLoS One</i> 2019; 14 . doi:10.1371/JOURNAL.PONE.0212293

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

559	36	Ha J, Choi DW, Kim KJ, et al. Association of metformin use with Alzheimer's disease
560		in patients with newly diagnosed type 2 diabetes: a population-based nested case-
561		control study. Scientific Reports 2021 11:1 2021;11:1-9. doi:10.1038/s41598-021-
562		03406-5
563	37	Zheng J, Xu M, Walker V, et al. Evaluating the efficacy and mechanism of metformin
564		targets on reducing Alzheimer's disease risk in the general population: a Mendelian
565		randomization study. <i>medRxiv</i> 2022;:2022.04.09.22273625.
566		doi:10.1101/2022.04.09.22273625
567	38	Luchsinger JA, Perez T, Chang H, et al. Metformin in Amnestic Mild Cognitive
568		Impairment: results of a pilot randomized placebo controlled clinical trial. J
569		Alzheimers Dis 2016;51:501. doi:10.3233/JAD-150493
570	39	Sportelli C, Urso D, Jenner P, et al. Metformin as a Potential Neuroprotective Agent in
571		Prodromal Parkinson's Disease—Viewpoint. Frontiers in Neurology 2020;11:556.
572		doi:10.3389/FNEUR.2020.00556/BIBTEX
573	40	Mor DE, Sohrabi S, Kaletsky R, et al. Metformin rescues Parkinson's disease
574		phenotypes caused by hyperactive mitochondria. Proc Natl Acad Sci USA
575		2020;117:26438–47.
576		doi:10.1073/PNAS.2009838117/SUPPL_FILE/PNAS.2009838117.SD02.XLSX
577	41	Lee ATC, Richards M, Chan WC, et al. Higher dementia incidence in older adults with
578		type 2 diabetes and large reduction in HbA1c. Age and Ageing 2019;48:838–44.
579		doi:10.1093/AGEING/AFZ108
580	42	Haw JS, Shah M, Turbow S, et al. Diabetes Complications in Racial and Ethnic
581		Minority Populations in the USA. <i>Current Diabetes Reports 2021 21:1</i> 2021; 21 :1–8.
582		doi:10.1007/S11892-020-01369-X
583	43	Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function,
584		and dementia: a systematic review. <i>Epidemiology</i> 2013;24:479-89.
585		doi:10.1097/EDE.0B013E3182944410
586	44	Okunoye O, Marston L, Walters K, et al. Change in the incidence of Parkinson's
587		disease in a large UK primary care database. npj Parkinson's Disease 2022 8:1
588		2022; 8 :1–7. doi:10.1038/s41531-022-00284-0
589	45	Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for
590		psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological
591		Psychiatry 2008;32:1362–74. doi:10.1016/J.PNPBP.2008.01.008
592	46	Schwartz TL, Siddiqui UA, Raza S. Memantine as an Augmentation Therapy for
593		Anxiety Disorders. Case Reports in Psychiatry 2012;2012:1-3.
594		doi:10.1155/2012/749796
595	47	Fereshtehnejad SM, Yao C, Pelletier A, et al. Evolution of prodromal Parkinson's
596		disease and dementia with Lewy bodies: a prospective study. Brain 2019;142:2051-
597		67. doi:10.1093/BRAIN/AWZ111
598	48	Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of Preclinical, Prodromal
599		and Dementia Alzheimer Disease Stages in Relation to Age, Sex, and APOE genotype.
600		Alzheimers Dement 2019;15:888. doi:10.1016/J.JALZ.2019.04.001
601	49	Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or
602		Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review
603		and Meta-analysis. Ann Intern Med 2016;164:740-51. doi:10.7326/M15-2650
604	50	Metformin in Alzheimer's Dementia Prevention - Full Text View - ClinicalTrials.gov.
605		https://clinicaltrials.gov/ct2/show/NCT04098666 (accessed 9 May 2022).
606		
607		

608 FIGURE LEGENDS

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk


609

610 Figure 1. Flow diagram sample population for this study after inclusion and exclusion 611 criteria; eGFR: Estimated glomerular filtration rate, HbA1c: Hemoglobin A1c; PCOS: 612 polycystic ovary syndrome; PD: Parkinson's Disease 613 Figure 2: Covariate balance between new users of metformin and sulfonylureas using 614 absolute Standardized Mean Differences (SMD) before (unweighted) and after inverse 615 probability of treatment weighting (weighted) for whole cohort (n = 112,591). Dotted 616 line indicates SMD cut off at 0.1 where >0.1 indicates difference in covariates between 617 the metformin and sulfonylurea users. CKD: Chronic Kidney Disease; eGFR: 618 Estimated glomerular filtration rate. HbA1c: haemoglobin A1c; COPD: Chronic 619 obstructive pulmonary disease, NSAIDs: Non-steroidal anti-inflammatory drugs 620 Figure 3: Forest plot showing IPTW weighted associations of primary and secondary


outcomes with new users of metformin versus sulfonylureas in whole population
 (over 50) and stratified for patients above and below 75 years of age HR: hazard ratio,
 Cl confidence interval, IPTW inverse probability treatment weight

Figure 4: Forest plot showing IPTW weighted associations of primary and secondary outcomes with new users of metformin versus sulfonylureas stratified by race, baseline renal function and baseline HbA1c. Renal function levels were defined as normal (eGFR > 90 mL/min), moderate (eGFR = 60-89 mL/min) and poor (eGFR = < 60 mL/min). HbA1c levels were defined as low < 7% and high => 7%. HR: hazard ratio, CI confidence interval, IPTW inverse probability treatment weight.

630







Outcomes	Group	Metformin (event/total)	Sulfonylureas (event/total)		HR (95% CI)
Primary Outcomes					
All Cause Dementia	> 50 years	2256/96140	951/16451	⊢● -1	0.803 (0.731 to 0.882)
	< 75 Years	1049/81258	215/9690	⊢ −●−−1	0.751 (0.632 to 0.892)
	> 75 years	1207/14882	736/6761	⊢−● −−1	0.882 (0.795 to 0.978)
PD	> 50 years	625/96140	135/16451	⊢	1.007 (0.794 to 1.277)
	< 75 Years	438/81258	66/9690		0.861 (0.635 to 1.167)
	> 75 years	187/14882	69/6761	↓	1.401 (1.005 to 1.954)
Secondary Outcomes					
Alzhiemer's Disease	> 50 years	754/94638	337/15837		0.807 (0.695 to 0.938)
	< 75 Years	294/80503	64/9539 +		0.796 (0.584 to 1.086)
	> 75 years	460/14135	273/6298		0.863 (0.731 to 1.020)
Vascular Dementia	> 50 years	349/94233	154/15654	⊢	0.793 (0.632 to 0.996)
	< 75 Years	174/80383	42/9517		0.751 (0.511 to 1.104)
	> 75 years	175/13850	112/6137		0.874 (0.672 to 1.138)
MCI	> 50 years	1414/93986	401/15612		0.905 (0.789 to 1.037)
	< 75 Years	874/80146	144/9487		0.868 (0.707 to 1.065)
	> 75 years	540/13840	257/6125		0.974 (0.826 to 1.149)
			0.5	0.8 1.0 1.2 1.5	

Favours Metformin

Favours Sulfonylureas

Outcomes	Group	Metformin (event/total)	Sulfonylureas (event/total)		HR (95% CI)
Race					
All Cause Dementia	Caucasian	1918/79693	841/13853	H O H	0.788 (0.712 to 0.871)
	African American	210/9659	66/1535		0.856 (0.617 to 1.187)
Parkinson's Disease	Caucasian	580/79693	120/13853		1.060 (0.822 to 1.368)
	African American	22/9659	7/1535		0.640 (0.234 to 1.752)
Alzheimer's Disease	Caucasian	641/78416	300/13312	· · · · · · · · · · · · · · · · · · ·	0.768 (0.654 to 0.901)
	African American	77/9526	24/1493		1.141 (0.676 to 1.925)
Vascular Dementia	Caucasian	284/78059	130/13142	⊢_ ● ¹	0.805 (0.630 to 1.030)
	African American	46/9495	19/1488		0.685 (0.364 to 1.289)
Mild Cognitive Impairment	Caucasian	1215/77876	364/13123	r ⊢⊕ <u>+</u> 1	0.902 (0.782 to 1.041)
	African American	129/9447	27/1467	, ,↓	0.805 (0.484 to 1.339)
Renal Function					
All Cause Dementia	Normal	618/46980	122/4464		0.833 (0.663 to 1.045)
	Moderate	1441/44276	505/7708	⊨ e ⊣ ¦	0.804 (0.715 to 0.904)
	Poor	197/4884	324/4279	k ⊕_ i	0.822 (0.659 to 1.023)
Parkinson's Disease	Normal	242/46980	27/4464	· · •	0.943 (0.606 to 1.467)
	Moderate	345/44276	68/7708	⊧ i	1.047 (0.767 to 1.431)
	Poor	38/4884	40/4279		1.159 (0.708 to 1.896)
Alzheimer's Disease	Normal	194/46556	39/4381	· · · · · · · · · · · · · · · · · · ·	0.913 (0.613 to 1.358)
	Moderate	496/43331	189/7392	F−●−−Į	0.818 (0.680 to 0.984)
	Poor	64/4751	109/4064	⊢ ● <u> </u>	0.703 (0.491 to 1.006)
Vascular Dementia	Normal	95/46457	16/4358	⊢ ⊢ i	1.006 (0.541 to 1.870)
	Moderate	223/43058	71/7274		0.810 (0.603 to 1.089)
	Poor	31/4718	67/4022	· · · · · · · · · · · · · · · · · · ·	0.586 (0.346 to 0.995)
Mild Cognitive Impairment	Normal	491/46321	63/4353	⊧ € 1	0.959 (0.706 to 1.301)
	Moderate	827/42968	209/7256		0.888 (0.747 to 1.056)
	Poor	96/4697	129/4003		0.812 (0.588 to 1.122)
HbA1c					
All Cause Dementia	Low	1520/62460	555/8583	F⊕-1 ¦	0.778 (0.688 to 0.881)
	High	736/33680	396/7868	⊢ ● −!	0.855 (0.745 to 0.982)
Parkinson's Disease	Low	418/62460	78/8583	⊢ ↓	0.920 (0.671 to 1.262)
	High	207/33680	57/7868		1.158 (0.819 to 1.639)
Alzheimer's Disease	Low	511/61451	193/8221	⊢ ●	0.817 (0.669 to 0.997)
	High	243/33187	144/7616		0.797 (0.637 to 0.998)
Vascular Dementia	Low	237/61177	80/8108		0.868 (0.633 to 1.192)
	High	112/33056	74/7546	⊢● ↓	0.673 (0.483 to 0.937)
Mild Cognitive Impairment	-	968/61041	235/8100		0.883 (0.737 to 1.059)
-	High	446/32945	166/7512		0.942 (0.769 to 1.154)
	-				·
			0.0	0.5 1.0 1.5 2.0	

Favours Metformin Favours Sulfonvlureas